{"id":"W2001129294","doi":"10.1016/j.clinthera.2005.08.001","title":"Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C β-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial","year":2005,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Pain Mechanisms and Treatments","field":"Medicine","cited_by":172,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Toronto","funders":"Eli Lilly and Company; American Diabetes Association","keywords":"Medicine; Mesylate; Placebo; Peripheral neuropathy; Double blind; Protein kinase C; Peripheral; Clinical trial; Randomized controlled trial; Internal medicine; Pharmacology; Kinase; Diabetes mellitus; Endocrinology; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00242333,0.0005573567,0.002795499,0.00008317967,0.0001796497,0.00006005026,0.0002246197,0.0003107801,0.00009444095],"category_scores_gemma":[0.0002335017,0.0002692685,0.001490357,0.0001918317,0.0006687183,0.00007014803,0.00004994475,0.0004676173,0.00004059949],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000126432,"about_ca_system_score_gemma":0.0002758579,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000007017544,"about_ca_topic_score_gemma":0.000008280865,"domain_scores_codex":[0.9941664,0.001737331,0.002298967,0.0006536703,0.0005959258,0.0005477398],"domain_scores_gemma":[0.995541,0.002160784,0.0008252798,0.0009826788,0.00016211,0.0003281186],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9799344,0.005738471,0.0008874887,0.00004765167,0.002575083,0.0001050032,0.0002329918,0.00001895767,0.0002529826,0.0002416998,0.000003553206,0.009961695],"study_design_scores_gemma":[0.980438,0.01110608,0.0003529465,0.000151749,0.003019367,0.0000249241,0.00007820411,0.00225357,0.001596914,0.00008734563,0.0006262334,0.0002646649],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.984363,0.0007339508,0.0001971254,0.002382311,0.0003620439,0.01151502,0.000007986033,0.00009685406,0.0003417814],"genre_scores_gemma":[0.9924217,0.0005849234,0.001982782,0.000403179,0.001380359,0.001198304,0.00001036733,0.0000922106,0.001926213],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01031671,"threshold_uncertainty_score":0.999976,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07598269146664982,"score_gpt":0.3738358848961089,"score_spread":0.297853193429459,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}